On June 6, the "R&D Without Borders · Sino Biopharmaceutical Sets Sail" International Biopharmaceutical Innovation and Development Forum was held at the Chia Tai Tianqing Global R&D Headquarters in Minhang District, Shanghai.

On May 22, Chia Tai Tianqing Pharmaceutical Group, a core enterprise of Sino Biopharmaceutical (1177.HK), donated 100 million yuan to the China Science and Technology Development Foundation. This move actively implements the national "15th Five-Year Plan" strategic layout, helps build the biopharmaceutical industry into a national emerging pillar industry, and empowers the nation's high-level scientific and technological self-reliance with concrete actions.

On May 14, the 6th CICC Healthcare Industry Summit 2026 was held in Shanghai. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical (1177.HK), attended and delivered a speech, providing a clear answer for achieving a global breakthrough through a differentiated M&A strategy for local Chinese pharmaceutical companies, combined with a leading advantage across the entire value chain.

Recently, S&P Global, an internationally authoritative sustainability assessment agency, held the launch ceremony for "The Sustainability Yearbook" (China Edition) 2026 in Shanghai.